Andrew John Fisher
Rank 10 by 10-year citations to CLAD papers (20 papers, 1,441 citations). "Professor of Respiratory Transplant Medicine" (NU Translational and Clinical Research Institute, Newcastle...; field: respiratory medicine.
As of . Primary source: ORCID record (role and affiliation entries are self-asserted).
Summary
Andrew John Fisher. Role: ORCID lists "Professor of Respiratory Transplant Medicine" (NU Translational and Clinical Research Institute, Newcastle University); "Professor of Respiratory Medicine" (Translational and Clinical Research, Newcastle University). Basis of the role: ORCID employment entries without an end date (some asserted by the named organisation, others by the record holder; may be out of date). Field indicated by the unit name: respiratory medicine (source: the same ORCID entries). Affiliation: Newcastle University, Newcastle upon Tyne (GB). Basis: ORCID record, employment entries without an end date (self-asserted, may be out of date). The whole-count rank depends substantially on consensus or guideline papers. Counts in the OpenAlex corpus (retrieved 2026-10-10): 20 papers and 1,441 citations over ten years; 1 first-author and 10 last-author papers. Ranks: main 10, excluding consensus papers 72, first or last author 40. The method is stated once on the People list page. Linked papers are the most-cited corpus papers of this author.
Citation ranks (10 years)
| Main rank | Rank excluding consensus papers | Rank by first or last author papers |
|---|---|---|
| 10 of 800 | 72 of 794 | 40 of 512 |
Citations: 1,441 in total, 389 excluding consensus and guideline papers (2 of this author's papers excluded), 181 on first or last author papers (1 first, 10 last).
Ranking method: see the methodology note at the top of the People list and the full methodology document.
Role and field
- Role
- "Professor of Respiratory Transplant Medicine" (NU Translational and Clinical Research Institute, Newcastle University); "Professor of Respiratory Medicine" (Translational and Clinical Research, Newcastle University)
- Role status
- verified from ORCID (entries asserted by the record holder or by the named organisation; may be out of date)
- Role basis
- ORCID employment entries without an end date (some asserted by the named organisation, others by the record holder; may be out of date)
- Field
- respiratory medicine
- Field basis
- the same ORCID entries
Only what a cited source supports is stated. Entries marked self-asserted come from the person's own ORCID record. The field is taken from the name of the unit, not inferred from the person's name.
Details
- affiliation
- Newcastle University, Newcastle upon Tyne (GB)
- papers 10y
- 20
- fractional papers 10y
- 3.23
- citations 10y
- 1441
- fractional citations 10y
- 136.8
- ranking retrieved
- 2026-10-10
- orcid
- 0000-0003-4822-7223
- openalex author id
- A5077353591
- merged open alex profiles
- 2
- affiliation basis
- ORCID record, employment entries without an end date (self-asserted, may be out of date)
- papers excluding consensus 10y
- 18
- citations excluding consensus 10y
- 389
- consensus papers excluded 10y
- 2
- first author papers 10y
- 1
- last author papers 10y
- 10
- lead author citations 10y
- 181
- lead author papers 10y
- 11
Sources and links
- ORCID record (role and affiliation entries are self-asserted) (primary)
- OpenAlex author profile (ranking source)
- Most-cited CLAD paper in corpus: Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment―A consensus report from the Pulmonary Council of the ISHLT (The Journal of Heart and Lung Transplantation, 2019); 952 citations; DOI 10.1016/j.healun.2019.03.009
- Most-cited CLAD paper in corpus: Immune processes in the pathogenesis of chronic lung allograft dysfunction: identifying the missing pieces of the puzzle (European Respiratory Review, 2022); 45 citations; DOI 10.1183/16000617.0060-2022
- Most-cited CLAD paper in corpus: Effector immune cells in chronic lung allograft dysfunction: A systematic review (Immunology, 2022); 26 citations; DOI 10.1111/imm.13458
- Most-cited CLAD paper in corpus: Extracorporeal photopheresis (ECP) in the treatment of chronic lung allograft dysfunction (CLAD): a prospective, multicentre, open-label, randomised controlled trial studying the addition of ECP to standard care in the treatment of bilateral lung transplant patients with CLAD (E-CLAD UK) (BMJ Open Respiratory Research, 2024); 15 citations; DOI 10.1136/bmjresp-2023-001995
- Most-cited CLAD paper in corpus: Lymphocyte Depleting and Modulating Therapies for Chronic Lung Allograft Dysfunction (Pharmacological Reviews, 2023); 12 citations; DOI 10.1124/pharmrev.123.000834
- ORCID employment entries (source of the role)
Related
Links from this record
Known gaps in this record
- centre membership relation (not asserted)
- funding and conflicts of interest
- whole-count rank depends substantially on consensus or guideline papers; see the rank excluding consensus papers
- whole-count rank depends substantially on consensus or guideline papers; see the rank excluding consensus papers
Information resource only. Not medical advice. Not a substitute for the care of the patient's transplant team.